Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma

• Main Authors: Toh, H.C., Chen, P.-J., Carr, B.I., Knox, J.J., Gill, S., Ansell, P., McKeegan, E.M., Dowell, B., Pedersen, M., Qin, Q., Qian, J., Scappaticci, F.A., Ricker, J.L., Carlson, D.M., Yong, W.P.
• Other Authors: CANCER SCIENCE INSTITUTE OF SINGAPORE
• Format: Article
• Published: 2014
• Subjects: angiogenesis; hepatocellular carcinoma (HCC); linifanib; platelet-derived growth factor receptor (PDGFR); sorafenib; vascular endothelial growth factor receptor (VEGFR)
• Online Access: http://scholarbank.nus.edu.sg/handle/10635/116518
• Institution: National University of Singapore

10.1002/cncr.27758